|
Proceedings
Day 3 - Thursday, October 21, 2004
Tissue Imaging – Localization of Drugs and Metabolites
Discussion Leader:Yunsheng Hsieh, Schering Plough Research Institute
The use of mass spectrometric techniques as an analytical tool has become
standard in pharmaceutical research and development. Mass spectrometry is
routinely applied throughout all phases of drug discovery and development,
from the synthesis of new chemical entities (for structural characterization)
to the analysis of lead compounds in clinical trials (for metabolite
identification and pharmacokinetics). This session will discuss various MS-based
imaging methodologies to provide useful information about the localization of
a given target in biological tissues.
Mapping Small Molecules in Intact Tissue by Laser Microprobe Ion Trap Tandem
Mass Spectrometry
Timothy Garrett and Richard Yost, University of Florida
Imaging Proteins in Tissues via MALDI Mass Spectrometry
Michelle L. Reyzer, Vanderbilt University
Imaging Mass Spectrometry for Probing the Brain
Stanislav Rubakhin, University of Illinois
Tissue Imaging Using MALDI Tandem Mass Spectrometry for Drug Candidates
Yunsheng Hsieh, Schering-Plough Research Institute
Biomarker Evaluation
Discussion Leaders: Bradley Ackermann, Eli Lilly and Company;
Sushmita M. Roy, SurroMed
This session will focus on strategies and techniques used in the difficult,
yet essential, process of translating candidate markers into tools that truly
guide pre-clinical and clinical pharmacology. The importance of cross-functional
partnerships, emerging technologies, and iterative learning will be emphasized.
Quantitation of Peptides & Protein Biomarkers by Mass Spectrometry
Brad Guild, Millennium
Analysis of Small Molecule Biomarkers
Susan K. Ohorodnik, SFBC-Taylor Technologies
Establishing Pre-Clinical and Clinical PK/PD Relationships
Carl Garner, Eli Lilly and Company
Lunch/Roundtables – Compound Library Analysis and Profiling
Discussion Leaders: Dalin Nie, AstraZeneca David Semin, Amgen
The success of drug discovery research relies upon the quality of the
corporate compound library. As compound stability can be affected by many
factors, it is important to assess the quality of the library over time.
Advances in analytical technologies made it possible. The discussion will be
focused on assessing the quality of compound library with analytical technology.
Emerging Technologies and Applications
Discussion Leader: David Wagner, GlaxoSmithKline
The last few decades has generated extraordinary technological
advancements in medicine, science, transportation, engineering, and
communication. These technologies have changed the way in which we
live our personal lives as well as scientists’ ability to conduct research.
New technologies are constantly being developed world wide in universities
and companies, and speculating which ones will transform science is challenging.
Several emerging areas of technology that should have a profound impact on the
pharmaceutical industry will be discussed. These advances incorporate
instrumentation, nanotechnology, and novel sample preparation. Each technology
will be highlighted exemplifying the potential and promise for the pharmaceutical
industry.
HPLC Chip Technology
Tom A. van de Goor, Agilent Technologies
Ion/Ion Methods for Peptide and Protein Sequence Analysis: Electron Transfer
Dissociation and Beyond
Joshua J. Coon, John E.P. Syka, Jeffrey Shabanowitz, Donald F. Hunt,
University of Virginia
Microwave-Enhanced Proteomic Applications – Rapid and Efficient Techniques
for Protein Analysis
J. Doug Ferguson, E. Keller Barnhardt, CEM Corporation
Wrap Up
Co-Chairs: Steven A. Hofstadler, Ibis Therapeutics
Mark Sanders, Bristol-Myers Squibb
|